Metastatic Hormone Refractory Prostate Cancer Completed Phase 2 Trials for Abiraterone (DB05812)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01503229Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment
NCT01487863Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerBasic Science
NCT02962284One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™Treatment
NCT01677897Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer PatientsTreatment